ClinicalTrials.gg
RecruitingNCT06990477Updated Jul 10, 2026

Effect of EIT-guided PEEP in ARDS Patients

An interventional study of EIT-guided PEEP in ARDS (Acute Respiratory Distress Syndrome), sponsored by Southeast University, China. Recruiting at 17 sites in 3 countries. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Southeast University, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,400
Allocation
Randomized
Ages
19 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Planned enrollment
Largest of 31
2,400 · median 60
Started
2026
with 7 others
No phase
20 of 59
6 open now
Primary completion
2029-12
later than 19 of 19 live
Registered
44th of 59
by date
Lead sponsor
5 of 59
Southeast University, China

Among the 59 studies in Acute Lung Injury with a site in China, this one has the largest planned enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2026, is one of 20 with no phase, reaches primary completion later than 19 of the 19 other live ones, and was the 44th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 19 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury. Positive end-expiratory pressure (PEEP), as one of main component of MV, has been widely used in the clinical practice. However, the PEEP selection is still a difficult problem for moderate to severe ARDS patients. EIT, an imaging tool evaluating the regional ventilation distribution at the bedside, can achieve the individual PEEP selection for all mechanically ventilated patients. Our previous study found that moderate to severe ARDS patients with higher recruitability could benefit from EIT-guided PEEP. This article compared the effect of PEEP titrated guided by EIT with fraction of inspired oxygen (FiO2)-PEEP table on the clinical outcomes in ARDS patients.

03

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)

Browse trials for

04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 years
  2. Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O)
  3. Diagnosis of ARDS less than 72 hours

Exclusion criteria

Exclusion Criteria:

  1. Expected to be mechanically ventilated for less than 48 hours
  2. Severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive MV
  3. Undrained pneumothorax or subcutaneous emphysema
  4. to the use of EIT (pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps)
  5. Severe neuromuscular disease
  6. Hemodynamic instability
  7. Contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome
  8. Severe other organs dysfunction with a low expected survival (7 days) or palliative care
  9. Severe liver disease ( Score ≥10)
  10. Pregnancy
  11. Refusal to sign the
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
2,400 participants (estimated)

Study arms

  • Experimental
    EIT-guided PEEP group

    Patients will receive PEEP titrated by EIT with a stepwise decrease PEEP trial

    Device: EIT-guided PEEP

  • No intervention
    low PEEP-FiO2 table group

    PEEP will be set according to the low FiO2-PEEP table to keep the oxygenation goals: SpO2 between 90% and 96%, and PaO2 between 60mmHg and 90mmHg.

Interventions

  • DeviceEIT-guided PEEP

    PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O or to 24cmH2O and then reduced in steps of 2cmH2O from 20 to 4 every 30s.

06

What researchers measure

Primary outcomes

  1. 28-day mortality

    Time frame: mortality in Day 28

07

Study locations

2 of 17 sites recruiting
08

References and documents

Publications

  • Yuan X, Chen D, Chao Y, Zhang R, Guo L, Xie J, Liu S, Zhao Z, Huang Y, Yang Y, Mauri T, Qiu H, Liu L. Effect of Individualized Positive End-Expiratory Pressure Titrated by Electrical Impedance Tomography in Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2025 Mar;211(3):418-421. doi: 10.1164/rccm.202411-2112RL. No abstract available. PubMed 39787604 ↗
  • Yuan X, Zhong M, Li Z, Sang L, Huang X, Zhang R, Chen H, Gao Y, Wang Y, Lin Z, Lu S, Yang F, Chen T, Guo L, Xie J, Zhao Z, Huang Y, Yang Y, Mauri T, Qiu H, Liu L; Chi-ARDS Net (Chinese ARDS Research Network). Electrical impedance tomography-guided positive end-expiratory pressure and mortality of patients with the acute respiratory distress syndrome: the EITVent randomized clinical trial. Am J Respir Crit Care Med. 2026 Mar 1;212(3):440-451. doi: 10.1093/ajrccm/aamaf125. PubMed 41738148 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2029, 45 months after the start.

Of 51 non-industry interventional studies with no phase under Acute Lung Injury, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 45 months is above that.

Counting every sponsor, half of 52 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2025
First posted
May 25, 2025
StartActual
Mar 13, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Feb 20, 2030
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06990477
Responsible party
Ling Liu (pH.D, Southeast University, China) — Principal investigator
First posted
May 25, 2025
Start date
Mar 13, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Feb 20, 2030 (estimated)
Last update
Jul 10, 2026

Study contacts

yuan xue yan, MD, MD
Contact
18826401594@163.com
+86 83262550

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion